Biogen Sinks Despite Raft of Analyst Upgrades
One day after flying sky high, Biogen (NASDAQ: BIIB) stock quickly obeyed gravity by falling marginally on Tuesday.
Interestingly, this came on a day when several analysts raised their price targets and/or recommendations on the stock. This was entirely expected, after the Food and Drug Administration (FDA) approved the company's aducanumab on Monday.
Image source: Getty Images.
Source Fool.com
